Response according to randomization for CLO
| . | Standard treatment (arm A), n = 166 . | CLO + standard treatment (arm B), n = 168 . |
|---|---|---|
| CR | ||
| After induction cycle 1, n (%) | 131 (79) | 131 (78) |
| After consolidation, n (%) | 143 (86) | 145 (86) |
| CR on protocol, n (%) | 148 (89) | 149 (89) |
| MRD negativity* | ||
| After RI 1 | 45/83 (54) | 62/88 (70) |
| After consolidation 1 | 54/76 (71) | 75/81 (93) |
| On protocol | 76/99 (77) | 88/101 (87) |
| Relapsed disease | ||
| Relapse after CR | 42/148 (28) | 36/149 (24) |
| Relapse in MRD− patients after consolidation 1 | 10/54 (19) | 13/72 (18) |
| Relapse in MRD+ patients after consolidation 1 | 8/20 (40) | 3/5 (60) |
| Nonrelapse mortality in CR, n (%) | ||
| ≤40 y | 5/71 (7) | 7/71 (10) |
| >40 y | 19/77 (25) | 17/78 (22%) |
| . | Standard treatment (arm A), n = 166 . | CLO + standard treatment (arm B), n = 168 . |
|---|---|---|
| CR | ||
| After induction cycle 1, n (%) | 131 (79) | 131 (78) |
| After consolidation, n (%) | 143 (86) | 145 (86) |
| CR on protocol, n (%) | 148 (89) | 149 (89) |
| MRD negativity* | ||
| After RI 1 | 45/83 (54) | 62/88 (70) |
| After consolidation 1 | 54/76 (71) | 75/81 (93) |
| On protocol | 76/99 (77) | 88/101 (87) |
| Relapsed disease | ||
| Relapse after CR | 42/148 (28) | 36/149 (24) |
| Relapse in MRD− patients after consolidation 1 | 10/54 (19) | 13/72 (18) |
| Relapse in MRD+ patients after consolidation 1 | 8/20 (40) | 3/5 (60) |
| Nonrelapse mortality in CR, n (%) | ||
| ≤40 y | 5/71 (7) | 7/71 (10) |
| >40 y | 19/77 (25) | 17/78 (22%) |
CR, complete remission; MRD, minimal residual disease; N, number of patients; RI, remission induction course.
Indicates the number of patients for whom a sample was obtained.